Publications
Publications
Show Results For
- All HBS Web
(312)
- Faculty Publications (70)
Genetics
→
- December 2006 (Revised January 2008)
- Case
ViaGen: Revolutionizing the Livestock Industry
By: David E. Bell, Reed Martin and Mary L. Shelman
ViaGen has invested heavily to develop cloning technology for the livestock industry. Cloning has the potential to significantly improve the genetics of livestock, leading to higher quality meat, healthier animals, and more efficient production. Since 2003, the firm... View Details
- December 2006 (Revised December 2007)
- Case
The Convention on Biological Diversity: Engaging the Private Sector
By: David E. Bell and Mary L. Shelman
The Convention on Biological Diversity (CBD) was a U.N. treaty that by 2006 had been signed by virtually every country in the world except for the United States. The treaty established three main goals: the conservation of biological diversity, the sustainable use of... View Details
- November 2006 (Revised March 2008)
- Case
The Harvard Stem Cell Institute
Describes a set of issues confronting the leaders of the Harvard Stem Cell Institute, an innovative cross-university effort to accelerate scientific discovery and translation in the domain of stem cells. Covers a wide range of topics, including understanding how... View Details
- May 2006 (Revised June 2006)
- Case
Codon Devices
By: Joseph B. Lassiter III and David Kiron
In December 2005, 40-year-old John Danner was about to make his first presentation to the board of directors of Codon Devices, a one-year-old biotechnology start-up based in Cambridge, Massachusetts. After a month as the company's CEO, Danner was prepared to lay out... View Details
- February 2006 (Revised August 2006)
- Case
deCODE Genetics: Hunting for Genes to Develop Drugs
By: Debora L. Spar
In 1996, Kari Stefansson launched a new kind of biotechnology company and a whole new way of attacking diseases. Based in Iceland, his firm, deCODE Genetics, plans to identify the individual genetic markers that lead to society's most prevalent diseases. To do so, it... View Details
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details
- June 2005 (Revised July 2006)
- Background Note
Note on the Convergence Between Genomics & Information Technology
By: David B. Yoffie, Dharmesh M Mehta and Rachel Sha
Focuses on the convergence between the genomics and semiconductor industries, in particular organ printing, DNA computing, biomolecular sensory networks, and DNA microarrays. Explains what this newly converged world looks like based on current research and findings in... View Details
- December 2003 (Revised April 2004)
- Case
Dragon's Teeth Vineyards
By: Alan D. MacCormack, Marius Leibold, Sven Voelpel and Kerry Herman
Dragon's Teeth Vineyards (DTV) is a South African wine producer that is considering whether to use genetically modified organisms (GMOs) in its wine-making process. GMOs promise to lower the costs of wine production significantly through increased yields and reduced... View Details
- October 2003 (Revised February 2004)
- Case
Launching the European Food Safety Authority
By: Ray A. Goldberg and Hal Hogan
The first food safety commission is established for the European Union. How does it handle food safety, scientific evaluations, and people's attitudes toward scientific changes in food growing and processing--for example, genetically modified organisms? View Details
- June 2003 (Revised March 2008)
- Case
Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene
By: Regina E. Herzlinger and Marc Aquino
Personalized medicine requires the identification of mutated genes. Schering-Plough's search for the one related to asthma requires finding families with the disease. Examines the industry that helps conduct such research, including contract research organizations. View Details
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details
- December 2002 (Revised April 2007)
- Case
Cargill (A)
By: Ray A. Goldberg and Jose M. M. Porraz
Cargill is one of the world's leading marketers, processors, and distributors of agricultural, food, industrial, and financial products. In 1998, the company decided to develop a strategic intent to restructure and refocus the company. It did so in response to the... View Details
- October 2002 (Revised February 2006)
- Case
Codex Alimentarius and Food Labeling
By: Ray A. Goldberg and Hal Hogan
Codex Alimentarius is a set of international food standards devised by the Codex Commission, a body within the United Nations jointly sponsored by the FAO and WHO. The purpose of the standards is to harmonize global trade in food products and agricultural commodities,... View Details
- January 2002 (Revised October 2005)
- Case
General Electric Medical Systems 2002
By: Tarun Khanna and James Weber
Discusses one of General Electric's flagship divisions--the world's leading provider of medical diagnostic imaging equipment. Provides an opportunity to examine a multinational confronting massive technological and demographic changes around the world. Genomics has... View Details
- December 2001
- Background Note
Reporting on Agribusiness in the 21st Century
By: Ray A. Goldberg and Anne M Fitzgerald
Agriculture is not what it used to be. Neither is coverage of the industry by news organizations. A century ago, about 40% of the U.S. population lived on the farm, and one in three U.S. jobs was tied to agriculture. It made sense for daily newspapers to cover farming... View Details
- October 2001
- Case
TIGR and ILRI: Solving Problems with Genomics
By: Ray A. Goldberg and James M Beagle
Discusses nonprofit institutional leadership applying advances in genetic science to solve health and animal problems in industrial countries and the developing world. View Details
- October 2001 (Revised April 2002)
- Case
Calgene, Inc.
By: Ray A. Goldberg and John T. Gourville
In 1993, Calgene is on the verge of introducing the world's first genetically engineered plant product--a tomato will taste better and stay fresh longer. At the same time, it is using biotechnology to produce improved plant products for the cottonseed and the... View Details
- October 2001 (Revised March 2002)
- Case
Perlegen Sciences
By: Linda A. Hill and Nicole Tempest
As a biotech start-up company involved in studying human genomes, Perlegen needed to develop an organization that fostered innovation and teamwork among a group of highly trained professionals from both the science and technology fields. Perlegen's CEO, Brad Margus,... View Details
- October 2001 (Revised March 2008)
- Case
Anagene, Inc.
By: Robert S. Kaplan and Christina L. Darwall
An entrepreneurial, publicly traded biotech company has begun production and sales of its core product--cartridges that permit DNA samples to be analyzed on a microchip. In the early quarters, sales are difficult to forecast and the company has experienced fluctuating... View Details
- August 2001
- Case
Finnigan Corporation
By: Carliss Y. Baldwin and Barbara Feinberg
Finnigan Corp., headquartered in San Jose, CA, was the world's leading producer of mass spectrometers, holding a 45% market share of instruments used for chemical analysis in pharmaceutical product development, environmental testing, genetic testing, and other... View Details